Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Nov 2021
Price :
$35
*
At a glance
- Drugs Estradiol (Primary)
- Indications Atrophic vaginitis; Dyspareunia
- Focus Registrational; Therapeutic Use
- Acronyms REJOICE
- Sponsors TherapeuticsMD
- 25 Sep 2021 Results of a post hoc analysis assessing the endometrial PR expression in menopausal women who used a vaginal 4- µ g or 10- µ g estradiol (E2) insert versus placebo presented at the North American Menopause Society 2021 Annual Meeting
- 03 Oct 2020 Results presented at the North American Menopause Society 2020 Annual Meeting
- 06 Oct 2018 Results assessing the Systemic Effects of TX-004HR in Menopausal Women with Moderate-to-Severe Dyspareunia, presented at the North American Menopause Society 2018 Annual Meeting